RIP1 (Receptor-Interacting Protein 1) is a protein kinase that plays a crucial role in cell signaling pathways, including those involved in inflammation, cell death, and cancer.
RIP1 is often overexpressed, and associated with poor prognosis.
RIP1 and RIP3 are key regulators of necroptosis and are involved in intricate signaling pathways that dictate cell survival, inflammation, and death.
Their dual roles in cancer can have opposing effects on tumor progression: while necroptosis may promote anti-tumor immunity and improve outcomes in some contexts, pro-survival signaling mediated by RIP1 can contribute to tumor aggressiveness and resistance to therapy.
RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1) — Multifunctional serine/threonine kinase and signaling scaffold that regulates cell survival, apoptosis, necroptosis, and inflammatory signaling downstream of receptors including TNFR1 and related death receptors.
Typical modulation in cancer: Context-dependent. RIPK1 can promote tumor-cell survival through scaffold-dependent NF-kB signaling, but its kinase activity can also promote RIPK1-dependent apoptosis or RIPK1/RIPK3-mediated necroptosis. Consequently, RIPK1 activation or inhibition may be beneficial depending on tumor type, pathway state, and treatment context.
Typical mechanistic relationships: TNF/TNFR1 → RIPK1 → NF-kB signaling and cell survival; or, under appropriate conditions, RIPK1 kinase activation → RIPK3 → MLKL phosphorylation/oligomerization → necroptosis. RIPK1 can also participate with FADD and caspase-8 in RIPK1-dependent apoptosis.
Necroptosis relevance: RIPK1 is a major upstream regulator of canonical necroptosis and can form a RIPK1-RIPK3 signaling complex (necrosome) leading to MLKL activation and membrane rupture.
|